

<b>Product Name</b>	D&O and Excess D&O
<b>Insurer</b>	AXA-XL Insurance Company UK Limited
<b>Responsible For Manufacture</b>	No
<b>Advised Sales</b>	No
<b>Product Type</b>	Financial lines / Management Liability
<b>Availability</b>	Manually underwritten / prior submit to insurers
<b>Target Market</b>	UK based commercial customers with more than one year trading history. The product is suitable for private limited companies, charities, clubs and associations.
<b>Non-Target Market (Unsuitable Markets)</b>	Non-Commercial customers.
<b>Why Is This Product Suitable</b>	Specifically designed Directors & Officers policy wording affording the relevant covers required for these persons of an insured entity.
<b>Are There Any Optional Covers</b>	Yes – can include corporate legal liability and employment practices cover.
<b>Distribution Methods</b>	SSR wholesale this product through other insurance intermediaries on behalf of AXA-XL Insurance Company UK Limited. This product can be obtained by SSR on a manual referral basis or through the Angel underwriting system, but ultimate underwriting of the product is AXA-XL Insurance Company UK Limited.
<b>Is This Product Providing Fair Value</b>	Yes, this product is deemed to be providing fair value as it is specifically targeted in terms of coverage and function and is distributed via insurance intermediaries who understand the requirements of their clients.
<b>Risk To Fair Value Mitigation</b>	Duplication of covers elsewhere or failure to purchase required optional elements. Excessive commission or fees may undermine the value of the product as well.  Care to be taken by distributors to ensure covers offered are not duplicating by other offerings. Commission levels charged by SSR and provided to distributors are within market norms and monitored for fairness regularly.
<b>Other Information To Consider</b>	Product documents can be provided upon request which clarifies position of product on standard exclusions and limitations to product coverage.  Product manufacturer/insurer will produce their own Fair Value Statement and Target Market Statement.

<b>Published</b>	September 2024
<b>Planned review</b>	September 2025